Article

Wavelight executives endorse Alcon offer

Erlangen, Germany-Furthering the friendly takeover process begun in July, the WaveLight AG executive committee and supervisory board have recommended that shareholders in the refractive surgery technology company tender their shares to Alcon Inc., according to a statement released by Alcon Inc.

Erlangen, Germany-Furthering the friendly takeover process begun in July, the WaveLight AG executive committee and supervisory board have recommended that shareholders in the refractive surgery technology company tender their shares to Alcon Inc., according to a statement released by Alcon Inc.

Alcon, incorporated in Huenenberg, Switzerland, with U.S. operations based in Fort Worth, TX, had increased its offer to the equivalent of approximately $20.45 U.S. per share, a 50% premium over its initial offer. The tender offer acceptance period will conclude Sept. 11. Alcon, which currently owns on a settled basis or has contractual commitments for more than 19% of WaveLight’s shares, has expressed an intention to increase its stake to at least 75% of WaveLight’s issued shares.

The news follows the German Federal Financial Supervisory Authority approval of publication of Alcon’s tender offer document, which is available online at http://www.alcon.com/investors-media/english-confirm.asp.

Newsletter

Don’t miss out—get Ophthalmology Times updates on the latest clinical advancements and expert interviews, straight to your inbox.

Related Videos
(Image credit: Ophthalmology Times) ASCRS 2025: Mark Lobanoff, MD, on making the move to office-based surgery
Barsha Lal, PhD, discusses the way low dose atropine affects accommodative amplitude and dynamics at the 2025 ARVO meeting
(Image credit: Ophthalmology Times) NeuroOp Guru: When eye findings should prompt neuroimaging in suspected neuro-Behcet disease
At the Association for Research in Vision and Ophthalmology (ARVO) meeting, Katherine Talcott, MD, a retina specialist at Cleveland Clinic, shared her findings on EYP-1901 (EyePoint Pharmaceuticals) in the phase 2 DAVIO study.
Dr. Jogin Desai, founder of Eyestem Research, discusses his research at the Association for Research in Vision and Ophthalmology.
(Image credit: Ophthalmology Times) ASCRS 2025: Michael Rivers, MD, shares his takeaways as a panelist at the inaugural SightLine event
(Image credit: Ophthalmology Times) ASCRS 2025: Karl Stonecipher, MD, on LASIK outcomes using an aspheric excimer laser for high myopia
John Tan talks about an emergency triage framework for retinal artery occlusion at the 2025 Association for Research in Vision and Ophthalmology (ARVO) meeting.
Dr Robert Maloney at the 2025 Controversies in Modern Eye Care meeting
Wendy Lee, MD, MS, at Controversies in Modern Eye Care 2025.
© 2025 MJH Life Sciences

All rights reserved.